In a 14-month follow-up, Sana Biotechnology has found that its investigational allogeneic cell therapy continued to produce insulin for one patient with Type 1 diabetes, with no safety concerns reported.
- Home |
- Sana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patient
Sana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patient
- March 13, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
